| Literature DB >> 32558876 |
Pamela H Lai1, Elizabeth A Lancet1, Michael D Weiden2,3, Mayris P Webber2,4, Rachel Zeig-Owens2,4,5, Charles B Hall6, David J Prezant1,2,5.
Abstract
Importance: Risk factors for out-of-hospital death due to novel coronavirus disease 2019 (COVID-19) are poorly defined. From March 1 to April 25, 2020, New York City, New York (NYC), reported 17 118 COVID-19-related deaths. On April 6, 2020, out-of-hospital cardiac arrests peaked at 305 cases, nearly a 10-fold increase from the prior year. Objective: To describe the characteristics (race/ethnicity, comorbidities, and emergency medical services [EMS] response) associated with outpatient cardiac arrests and death during the COVID-19 pandemic in NYC. Design, Setting, and Participants: This population-based, cross-sectional study compared patients with out-of-hospital cardiac arrest receiving resuscitation by the NYC 911 EMS system from March 1 to April 25, 2020, compared with March 1 to April 25, 2019. The NYC 911 EMS system serves more than 8.4 million people. Exposures: The COVID-19 pandemic. Main Outcomes and Measures: Characteristics associated with out-of-hospital arrests and the outcomes of out-of-hospital cardiac arrests.Entities:
Year: 2020 PMID: 32558876 PMCID: PMC7305567 DOI: 10.1001/jamacardio.2020.2488
Source DB: PubMed Journal: JAMA Cardiol Impact factor: 14.676
Figure. New York City Out-of-Hospital Nontraumatic Cardiac Arrest Resuscitations, March 1 through April 25, 2020
A, Temporal association between the cumulative percentage of emergency medical services (EMS) calls for fever, cough, dyspnea, and viral-like symptoms consistent with coronavirus disease 2019 (COVID-19) and the number of excess out-of-hospital nontraumatic cardiac arrest resuscitations occurring in New York City in 2020. Excess cases were defined as the daily difference between the number of 2020 and 2019 cases; days with a negative difference were recoded as 0 for graphic presentation. B, The number of daily out-of-hospital nontraumatic cardiac arrest resuscitations.
Patient Characteristics of Out-of-Hospital Nontraumatic Cardiac Arrests During COVID-19 and 1 Year Before
| Characteristic | Cardiac arrest resuscitations | |||
|---|---|---|---|---|
| Main analysis (n = 5325) | Sensitivity analysis peak period (n = 2292) | |||
| Comparison period (n = 1336) | COVID-19 period (n = 3989) | Comparison period (n = 341) | COVID-19 period (n = 1951) | |
| Age, mean (SD), y | 68 (19) | 72 (18) | 69 (18) | 72 (15) |
| Male | 752 (57.1) | 2183 (55.8) | 200 (59.9) | 1085 (57.0) |
| Race | ||||
| White | 382 (32.9) | 611 (20.4) | 87 (30.3) | 244 (17.6) |
| Asian | 88 (7.6) | 218 (7.3) | 19 (6.6) | 96 (6.9) |
| Black | 332 (28.6) | 1025 (34.3) | 89 (31.0) | 486 (35.0) |
| Hispanic | 239 (20.6) | 763 (25.5) | 64 (22.3) | 391 (28.1) |
| Mixed | 120 (10.3) | 375 (12.5) | 28 (9.8) | 172 (12.4) |
| Medical history | ||||
| Cardiac disease | 397 (29.7) | 1008 (25.3) | 105 (30.8) | 465 (23.8) |
| Hypertension | 611 (45.7) | 2134 (53.5) | 157 (46.0) | 1039 (53.3) |
| Diabetes | 348 (26.0) | 1424 (35.7) | 81 (23.8) | 708 (36.3) |
| Renal disease | 105 (7.9) | 313 (7.8) | 28 (8.2) | 137 (7.0) |
| Asthma/COPD | 214 (16.0) | 509 (12.8) | 57 (16.7) | 227 (11.6) |
| Cancer | 125 (9.4) | 282 (7.1) | 39 (11.4) | 114 (5.8) |
| CVA | 90 (6.7) | 228 (5.7) | 20 (5.9) | 114 (5.8) |
| Physical limitations | 634 (47.5) | 2259 (56.6) | 164 (48.1) | 1128 (57.8) |
| Bystander witnessed | 404 (30.2) | 1080 (27.1) | 106 (31.1) | 516 (26.4) |
| Bystander CPR | 441 (33.0) | 1359 (34.1) | 109 (32.0) | 657 (33.7) |
| Presenting rhythm | ||||
| Ventricular rhythms | 38 (11.0) | 45 (3.6) | 13 (13.8) | 17 (2.9) |
| Asystole | 209 (60.6) | 973 (77.6) | 53 (56.4) | 475 (80.7) |
| PEA | 72 (20.9) | 177 (14.1) | 21 (22.3) | 64 (10.9) |
Abbreviations: COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CPR, cardiopulmonary resuscitation; CVA, cerebrovascular accident; PEA, pulseless electrical activity.
Study population used for these estimates includes only patients who received resuscitation by emergency medical services. Unless otherwise indicated, data are expressed as number (percentage) of patients.
Covers March 1 to April 25, 2019 (comparison period) and 2020 (COVID-19 period).
Covers March 29 to April 11, 2019 (comparison period) and 2020 (COVID-19 period).
Owing to missing data, includes 1316 for the main analysis comparison period, 3915 for the main analysis COVID-19 period, 334 for the sensitivity analysis comparison period, and 1902 for the sensitivity analysis COVID-19 period.
Owing to missing data, includes 1161 for the main analysis comparison period, 2992 for the main analysis COVID-19 period, 287 for the sensitivity analysis comparison period, and 1389 for the sensitivity analysis COVID-19 period.
Owing to missing data, includes 345 for the main analysis comparison period, 1254 for the main analysis COVID-19 period, 94 for the sensitivity analysis comparison period, and 589 for the sensitivity analysis COVID-19 period. Presenting rhythm data were only collected for those out-of-hospital cardiac arrests in which an advanced life support unit was first on the scene.
Ventricular rhythms include ventricular fibrillation and ventricular tachycardia.
Association of Risk Factors With Out-of-Hospital Nontraumatic Cardiac Arrests in the COVID-19 Period vs 1 Year Before
| Risk factor | Main analysis | Sensitivity analysis peak period | ||
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Age (per 10 y) | 1.12 (1.07-1.18) | <.001 | 1.16 (1.05-1.27) | .003 |
| Sex | ||||
| Female | 1 [Reference] | 1 [Reference] | ||
| Male | 0.92 (0.79-1.06) | .25 | 1.05 (0.79-1.39) | .74 |
| Race/ethnicity | ||||
| White | 1 [Reference] | 1 [Reference] | ||
| Asian | 1.43 (1.08-1.91) | .01 | 1.82 (1.01-3.28) | .05 |
| Black | 1.90 (1.57-2.29) | <.001 | 1.91 (1.33-2.74) | <.001 |
| Hispanic | 2.06 (1.68-2.52) | <.001 | 2.28 (1.54-3.37) | <.001 |
| Mixed | 1.96 (1.52-2.53) | <.001 | 1.99 (1.21-3.28) | .007 |
| Medical history | ||||
| Cardiac disease | 0.72 (0.61-0.86) | <.001 | 0.67 (0.49-0.93) | .02 |
| Hypertension | 1.28 (1.09-1.50) | .002 | 1.27 (0.94-1.73) | .12 |
| Diabetes | 1.45 (1.23-1.71) | <.001 | 1.81 (1.31-2.51) | <.001 |
| Renal disease | 0.79 (0.60-1.03) | .08 | 0.64 (0.39-1.06) | .09 |
| Asthma/COPD | 0.78 (0.64-0.95) | .02 | 0.67 (0.45-0.99) | .05 |
| Cancer | 0.72 (0.56-0.92) | .009 | 0.59 (0.37-0.94) | .03 |
| CVA | 0.70 (0.52-0.94) | .02 | 0.74 (0.41-1.32) | .30 |
| Physical limitations | 1.27 (1.09-1.49) | .002 | 1.38 (1.03-1.86) | .04 |
| Presenting rhythm | ||||
| Ventricular rhythms | 1 [Reference] | 1 [Reference] | ||
| Asystole | 3.50 (2.53-4.84) | <.001 | 5.37 (3.01-9.58) | <.001 |
| PEA | 1.99 (1.31-3.02) | .001 | 2.77 (1.29-5.91) | .009 |
Abbreviations: COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CVA, cerebrovascular accident; OR, odds ratio; PEA, pulseless electrical activity.
Study population used for these estimates includes only those out-of-hospital cardiac arrests who received resuscitation by emergency medical services.
Covers March 1 to April 25, 2019 (comparison period) and 2020 (COVID-19 period).
Covers March 29 to April 11, 2019 (comparison period) and 2020 (COVID-19 period).
Presenting rhythm data were only collected for those out-of-hospital cardiac arrests in which an advanced life support unit was first on the scene; however, an unclassified category was added for missing data to bolster model observations.
Ventricular rhythms include ventricular fibrillation and ventricular tachycardia.
Outcomes of Patients With Out-of-Hospital Nontraumatic Cardiac Arrest Resuscitations in the COVID-19 Period vs 1 Year Before
| Variable | Cardiac arrest resuscitations | |||
|---|---|---|---|---|
| Main analysis (n = 5325) | Sensitivity analysis peak period (n = 2292) | |||
| Comparison period (n = 1336) | COVID-19 period (n = 3989) | Comparison period (n = 341) | COVID-19 period (n = 1951) | |
| ROSC, No. (%) | 463 (34.7) | 727 (18.2) | 133 (39.0) | 297 (15.2) |
| Sustained ROSC, No. (%) | 337 (25.2) | 423 (10.6) | 96 (28.2) | 153 (7.8) |
| Resuscitation terminated in field | 999 (74.8) | 3566 (89.4) | 245 (71.9) | 1798 (92.2) |
| Time to first unit on scene, median (IQR), min:s | 5:05 (2:17-7:13) | 5:56 (2:14-9:38) | 5:03 (2:36-7:30) | 6:38 (2:08-10:28) |
| Time to ALS unit on scene, median (IQR), min:s | 7:32 (2:27-13:17) | 9:60 (0:43-19:17) | 7:22 (2:24-12:20) | 11:17 (1:07-22:07) |
| Total resuscitation time, median (IQR), min:s | 34:58 (20:15-49:01) | 32:18 (16:33-48:03) | 35:17 (21:14-49:20) | 30:55 (16:18-45:32) |
| ALS unit first on scene, No. (%) | 345 (25.8) | 1254 (31.4) | 94 (27.6) | 589 (30.2) |
| Shock delivered prior to ALS unit arrival, No. (%) | 79 (5.9) | 109 (2.7) | 20 (5.9) | 43 (2.2) |
| Airway, No. (%) | ||||
| Endotracheal intubation | 1011 (75.7) | 1915 (48.0) | 245 (71.8) | 825 (42.3) |
| Supraglottic airway | 193 (14.4) | 1385 (34.7) | 59 (17.3) | 706 (36.2) |
| Bag valve mask | 132 (9.9) | 689 (17.3) | 37 (10.9) | 420 (21.5) |
| Medications administered, No. (%) | ||||
| None | 75 (5.6) | 455 (11.4) | 27 (7.9) | 312 (16.0) |
| Epinephrine | 1238 (92.7) | 3516 (88.1) | 310 (90.9) | 1633 (83.7) |
| Amiodarone | 143 (10.7) | 231 (5.8) | 33 (9.7) | 77 (3.9) |
| Dextrose | 193 (14.4) | 328 (8.2) | 40 (11.7) | 132 (6.8) |
| Sodium bicarbonate | 598 (44.8) | 909 (22.8) | 164 (48.1) | 302 (15.5) |
| Naloxone | 89 (6.7) | 67 (1.7) | 19 (5.6) | 17 (0.9) |
| Magnesium | 43 (3.2) | 38 (1.0) | 4 (1.2) | 9 (0.5) |
Abbreviations: ALS, advanced life support; COVID-19, coronavirus disease 2019; IQR, interquartile range; ROSC, return of spontaneous circulation.
Study population used for these estimates includes only those with out-of-hospital cardiac arrests who received resuscitation by emergency medical services.
Covers March 1 to April 25, 2019 (comparison period) and 2020 (COVID-19 period).
Covers March 29 to April 11, 2019 (comparison period) and 2020 (COVID-19 period).
ROSC and sustained ROSC are not mutually exclusive, but patients must be either in sustained ROSC or have resuscitation terminated.
Association of COVID-19 With ROSC and Sustained ROSC Adjusted for Demographics, Interventions, and Response Time
| Intervention or risk factor | ROSC | Sustained ROSC | ||||||
|---|---|---|---|---|---|---|---|---|
| Main analysis | Sensitivity analysis peak period | Main analysis | Sensitivity analysis peak period | |||||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |||||
| Study period | ||||||||
| Comparison | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] | ||||
| COVID-19 | 0.59 (0.50-0.70) | <.001 | 0.44 (0.32-0.60) | <.001 | 0.53 (0.43-0.64) | <.001 | 0.38 (0.26-0.56) | <.001 |
| Age (per 10 y) | 1.00 (0.96-1.05) | .97 | 0.92 (0.84-1.01) | .07 | 0.97 (0.91-1.02) | .25 | 0.90 (0.81-1.01) | .07 |
| Sex | ||||||||
| Female | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] | ||||
| Male | 1.53 (1.31-1.79) | <.001 | 1.55 (1.18-2.04) | .002 | 1.59 (1.32-1.93) | <.001 | 1.60 (1.13-2.25) | .007 |
| Race/ethnicity | ||||||||
| White | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] | ||||
| Asian | 1.11 (0.81-1.52) | .52 | 1.09 (0.62-1.91) | .76 | 1.16 (0.80-1.68) | .44 | 0.77 (0.37-1.61) | .49 |
| Black | 0.79 (0.64-0.98) | .03 | 0.73 (0.50-1.06) | .10 | 0.68 (0.53-0.87) | .002 | 0.60 (0.38-0.95) | .03 |
| Hispanic | 0.89 (0.72-1.12) | .33 | 0.94 (0.64-1.39) | .77 | 0.86 (0.66-1.11) | .25 | 0.78 (0.48-1.25) | .30 |
| Mixed | 1.12 (0.85-1.48) | .41 | 1.10 (0.67-1.80) | .70 | 1.21 (0.89-1.65) | .23 | 1.19 (0.66-2.12) | .56 |
| Medical history | ||||||||
| Cardiac disease | 1.13 (0.94-1.36) | .18 | 0.93 (0.67-1.28) | .65 | 1.30 (1.05-1.61) | .02 | 1.16 (0.78-1.72) | .47 |
| Hypertension | 0.98 (0.83-1.17) | .84 | 1.09 (0.81-1.46) | .59 | 1.00 (0.82-1.23) | .98 | 1.12 (0.77-1.63) | .56 |
| Diabetes | 0.93 (0.77-1.11) | .39 | 0.78 (0.58-1.06) | .11 | 0.85 (0.68-1.05) | .14 | 0.83 (0.56-1.23) | .35 |
| Renal disease | 1.22 (0.92-1.62) | .17 | 1.29 (0.79-2.12) | .31 | 1.28 (0.92-1.79) | .15 | 0.95 (0.49-1.82) | .87 |
| Asthma/COPD | 1.30 (1.05-1.61) | .02 | 1.20 (0.82-1.76) | .35 | 1.32 (1.03-1.70) | .03 | 1.27 (0.80-2.03) | .31 |
| Cancer | 1.11 (0.83-1.47) | .48 | 0.98 (0.60-1.63) | .95 | 0.98 (0.70-1.39) | .93 | 0.81 (0.42-1.56) | .52 |
| CVA | 0.75 (0.52-1.06) | .11 | 1.01 (0.56-1.81) | .97 | 0.83 (0.55-1.25) | .36 | 1.33 (0.67-2.63) | .41 |
| Physical limitations | 0.56 (0.47-0.67) | <.001 | 0.74 (0.55-1.00) | .05 | 0.59 (0.47-0.73) | <.001 | 0.73 (0.50-1.07) | .10 |
| Bystander CPR | ||||||||
| No | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] | ||||
| Yes | 1.18 (0.99-1.40) | .06 | 1.27 (0.95-1.71) | .11 | 1.31 (1.07-1.60) | .009 | 1.52 (1.06-2.19) | .02 |
| Response time, min | ||||||||
| ≥6 | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] | ||||
| <6 | 1.09 (0.93-1.28) | .30 | 1.06 (0.81-1.40) | .66 | 1.38 (1.13-1.69) | .002 | 1.32 (0.93-1.88) | .12 |
| ALS unit first on scene | ||||||||
| No | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] | ||||
| Yes | 2.44 (1.60-3.73) | <.001 | 2.70 (1.31-5.58) | .007 | 2.84 (1.81-4.45) | <.001 | 3.29 (1.49-7.22) | .003 |
| ALS medication administration | ||||||||
| No | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] | ||||
| Yes | 1.65 (1.08-2.52) | .02 | 2.46 (1.24-4.89) | .01 | 1.25 (0.78-1.99) | .36 | 1.81 (0.80-4.07) | .15 |
| Airway maintenance | ||||||||
| Endotracheal intubation | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] | ||||
| Supraglottic airway | 0.48 (0.40-0.58) | <.001 | 0.52 (0.39-0.71) | <.001 | 0.41 (0.32-0.52) | <.001 | 0.50 (0.33-0.74) | <.001 |
| Bag valve mask | 0.50 (0.37-0.68) | <.001 | 0.50 (0.29-0.85) | .01 | 0.60 (0.42-0.86) | .005 | 0.57 (0.29-1.09) | .09 |
| Presenting rhythm | ||||||||
| Ventricular rhythms | 1 [Reference] | 1 [Reference] | 1 [Reference] | 1 [Reference] | ||||
| Asystole | 0.26 (0.17-0.41) | <.001 | 0.21 (0.10-0.44) | <.001 | 0.25 (0.15-0.41) | <.001 | 0.16 (0.07-0.36) | <.001 |
| PEA | 0.56 (0.33-0.95) | .03 | 0.60 (0.25-1.47) | .27 | 0.50 (0.29-0.89) | .02 | 0.36 (0.13-0.98) | .05 |
Abbreviations: ALS, advanced life support; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CPR, cardiopulmonary resuscitation; CVAs, cerebrovascular accidents; NA, not applicable; OR, odds ratio; PEA, pulseless electrical activity; ROSC, return of spontaneous circulation.
Study population used for these estimates includes only those with out-of-hospital cardiac arrests who received resuscitation by emergency medical services. Main study period covered March 1 to April 25, 2019 (comparison period) and 2020 (COVID-19 period); sensitivity time period, March 29 to April 11, 2019 (comparison period) and 2020 (COVID-19 period).
Calculated using logistic regression.
Presenting rhythm data were only collected for those out-of-hospital cardiac arrests in which an ALS unit was first on the scene; however, an unclassified category was added for missing data to bolster model observations.
Ventricular rhythm includes ventricular fibrillation and ventricular tachycardia.